

W T S

ARTICLE DELIVERY

WTS Number: 164422



Order #132594

**4-hour
rush**

Request Date: 06/16/2017 10:01am

Requester: Helen Sullivan - Prior Art Documentation Services LLC

Phone: 2174465370

Reference: 17603

Delivery email: helen@priorartdocs.com

Estimated Delivery:

06/16/2017
02:15pm

Maxcost:

Instructions: We need copy from print only and must have a date stamp and cover if possible. We have not been able to obtain a copy with a date stamp but a colleague has informed us he was able to obtain abstracts from this volume from your service.

Citation:

Follow up to 164380 -
Date stamp from BRI with introduction if available
Circulation, V.110, No. 17, Supplement .

Library/Supplier: BRI 01763913

ISSN/ISBN/OCLC: 0009-7322

Base Service Fee: \$15 **Rush fee:** \$20.00

Copyright: WTS will pay copyright royalties and bill me: \$ _____ pages: _____

Supplier: WTS staff may obtain materials from outside UW - Madison: \$ _____

Shipping: \$ _____ **Research:** \$ _____

THIS IS NOT AN INVOICE

ol 110, No 17, October 26, 2004
SN 0009-7322
http://circ.ahajournals.org

SUPPLEMENT TO

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

CIRCULATION.

BOSTON SPA
LS23 78Q



3265.200000

ETOC
CC List
Easy
PB

Volume 110: Number 17
(2004: Oct. 26) Supplement

Suppl.

Abstracts
from

LOAN BAN

EXPIRES

22 MAY 2005

Sessions: November 7-10
Exhibits: November 7-9
New Orleans, Louisiana
scientificsessions.org

scientific
sessions
2004



basic science



clinical science



population science

Named and Invited Lectures 2004

2004 Russell Ross Memorial Lectureship in Vascular Biology • 2004 George Lyman Duff Memorial Lecture • 2004 Sol Sherry Distinguished Lecture in Thrombosis • 2004 Thomas W. Smith Memorial Lecture • 2004 George E. Brown Memorial Lecture • 2004 Dickinson W. Richards Memorial Lecture • 2004 Katharine A. Lembricht Award • 2004 William W. L. Glenn Lecture • 2004 William J. Rashkind Memorial Lecture • 2004 T. Duckett Jones Memorial Lecture • 2004 Charles T. Dotter Memorial Lecture • 2004 Laennec Society Lecture • 2004 Ancel Keys Lecture • 2004 Lewis K. Dahl Memorial Lecture • 2004 Robert L. Levy Endowed Lecture in Lipid Metabolism

New and Young Investigator Award/Prize Abstract Finalists

Lewis N. and Arnold M. Katz Basic Science Research Prize for Young Investigators • Melvin L. Marcus Young Investigator Awards in Cardiovascular Science • Cournand and Comroe Young Investigators Prizes in Cardiopulmonary and Critical Care • Outstanding Research Award in Pediatric Cardiology • Melvin Judkins Young Investigator Award in Cardiovascular Radiology • Vivian Thomas Young Investigator Award • Martha N. Hill New Investigator Awards • Elizabeth Barrett-Connor Research Award in Epidemiology and Prevention for Investigators in Training • Samuel A. Levine Young Clinical Investigator Awards • Laennec Society Young Clinician Award • NPAM New Investigator Award

Abstracts From the Scientific Sessions 2004

Supplement to Circulation

Abstracts From Scientific Sessions 2004

Committee on Scientific Sessions Program

The American Heart Association is most grateful to members of the Committee on Scientific Sessions Program for their continued dedication and leadership throughout the year in planning the program.

Raymond J Gibbons, Chairman
Timothy Gardner, Vice Chairman

Council Representatives

Donna Arnett, Functional Genomics and Translational Biology Interdisciplinary Working Group
Kenneth Bloch, Cardiopulmonary Perioperative and Critical Care
Roberto Bolli, Member-at-Large
Lawrence Brass, Stroke Council
Blase A. Carabello, Clinical Cardiology
Arlene Chapman, Kidney in Cardiovascular Disease
Mark A. Creager, Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group
Alan Daugherty, Arteriosclerosis, Thrombosis, and Vascular Biology
Christi Deaton, Cardiovascular Nursing
David D. Gutterman, Basic Cardiovascular Sciences
David M. Herrington, Epidemiology and Prevention
Mariell Jessup, Member-at-Large
Alan Kadish, Member-at-Large
John Kugler, Cardiovascular Disease in the Young
Bruce Lerman, American College of Cardiology, Liaison
George A. Mensah, Member-at-Large
Richard C. Pasternak,* Member-at-Large
Robert C. Robbins, Cardiovascular Surgery and Anesthesia
David Robertson, High Blood Pressure Research
Beatriz Rodriguez, Nutrition, Physical Activity, and Metabolism
Arthur Stillman, Cardiovascular Radiology and Intervention
Robert Talbert, Member-at-Large
Gordon F. Tomaselli, Basic Cardiovascular Sciences
William S Weintraub, Quality of Care and Outcomes Research Interdisciplinary Working Group
William Wijns, European Society of Cardiology, Liaison

American Heart Association

Alice K. Jacobs, President
Augustus O. Grant, Immediate Past President
Rose Marie Robertson, Chief Science Officer

*Former member

Supplements to *Circulation* Published in 2004

Supplements to Circulation are published occasionally and for archival purposes may be bound with the regular issue. Supplement page numbers are preceded by a Roman numeral and a hyphen. Supplements are indexed with the regular issue with the exception of the Abstracts issue, which is indexed within that issue.

Diagnosis of Venous Thromboembolism Supplement

Gregory L. Moneta, MD, *Guest Editor*

Volume 109, Issue 12. March 30, 2004. Pages I-1-I-27.

Vascular Effects of Statins

Peter Libby, MD, *Guest Editor*

Volume 109, Issue 21. June 1, 2004. Pages II-1-II-48.

Atherosclerosis: Evolving Vascular Biology and Clinical Implications

Antonio M. Gotto, Jr, MD, DPhil, *Guest Editor*

Volume 109, Issue 23. June 15, 2004. Pages III-1-III-57.

Markers of Malign Across the Cardiovascular Continuum: Interpretation and Application

Victor J. Dzau, *Guest Editor*

Volume 109, Issue 25. June 29, 2004. Pages IV-1-IV-58.

Treatment of Venous Thromboembolism

Jeffrey I. Weitz, MD, *Guest Editor*

Volume 110, Issue 9. August 31, 2004. Pages I-1-I-34.

Cardiovascular Surgery Supplement 2004

Robert C. Robbins, MD, *Guest Editor*

Volume 110, Issue 14. September 14, 2004. Pages II-1-II-286.

Abstracts From Scientific Sessions 2004

Volume 110, Issue 17. October 26, 2004. Pages III-1-III-1102.

For rate and order information, contact

Lippincott Williams & Wilkins
Subscription Fulfillment Dept
351 West Camden Street
Baltimore, MD 21201-2436 USA
Telephone (410) 361-8080
Fax (410) 361-8048

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Editor-in-Chief

Joseph Loscalzo

Deputy Editor

Joseph A. Vita

Senior Associate Editor

Elliott M. Antman

Associate Editors

Gary J. Balady Emelia J. Benjamin Wilson S. Colucci Ravin Davidoff Jane E. Freedman John F. Keaney, Jr.
Jane A. Leopold Jane W. Newburger Douglas B. Sawyer Richard J. Shemin William G. Stevenson James E. Udelson Kenneth Walsh

Africa

Lionel Opie

Asia

Shigetake Sasayama

Australia/New Zealand

Harvey D. White

Central/South America

Edgardo Escobar

Europe

Thomas F. Lüscher

Staff

Managing Editor, Karen Barry

Assistant Managing Editors, Dale R. Golden and Doreen E. Kriegel

Consultants

Immediate Past Editor, James T. Willerson

Statistical Consultant, Martin G. Larson

Editorial Board

Philip Aedes
Charles Antzelevitch
Paul W. Armstrong
Robert J. Bache
Donald S. Baun
William H. Barry
Robyn J. Barst
Craig T. Basson
Anton E. Becker
George E. Beller
Ivor J. Benjamin
Bradford C. Berk
Michel E. Bertrand
Christoph Bode
Roberto Bolli
Robert O. Bonow
Jeffrey S. Borer
Penelope A. Boyden
Eugene Braunwald
Michael R. Bristow
Joan Heller Brown
Nancy J. Brown
Martina Brueckner
Robert M. Califf
Francois Cambien
Richard O. Cannon III
Oscar Carretero
Alan Chait
Bernard R. Chaitman
Peng-Sheng Chen
William M. Chilian
Alexander Clowes
David J. Cohen
Lawrence H. Cohn
Antonio Colombo
John P. Cooke
Delos M. Cosgrove
Filippo Crea
Mark A. Creager
Henry J. Dargie
John E. Deanfield
Linda L. Demer
David Dichek
John P. DiMarco
Stephanie Dimmeler
Gerald W. Dorn II
Helmut Drexler
Victor Dzau
Elazer R. Edelman
Eric J. Eichhorn
Stephen G. Ellis
Stephen E. Epstein

Michael D. Ezekowitz
Erling Falk
David P. Faxon
Douglas T. Fearon
James J. Ferguson III
Loren J. Field
Toren Finkel
Michael Fishbein
Glen I. Fishman
Desmond J. Fitzgerald
Garret A. FitzGerald
Alan M. Fogelman
Aaron R. Folsom
Thomas L. Force
Gregory L. Freeman
Victor Froelicher
Curt D. Furberg
Valentin Fuster
William H. Gaasch
Marie D. Gerhard-Herman
Bernard J. Gersh
Gary Gibbons
Raymond Gibbons
C. Michael Gibson
Samuel S. Gidding
Richard F. Gillum
Charles J. Glueck
Pascal J. Goldschmidt
Paolo Golino
Stephen S. Gottlieb
Augustus O. Grant
Paul A. Grayburn
Scott M. Grundy
Steven M. Haffner
Michel Haïssaguerre
Christian W. Hamm
Goran K. Hansson
Gerd Hasenfuss
Otto M. Hess
Charles B. Higgins
Joseph A. Hill
L. David Hillis
Karen Hirschi
Helen H. Hobbs
Judith S. Hochman
David R. Holmes, Jr.
Jeffrey D. Hosenpud
O. Wayne Isom
David A. Kass
Arnold M. Katz
Sanjiv Kaul
Chuchi Kawai

David M. Kaye
Mark T. Keating
Daniel P. Kelly
Dean J. Kereiakes
Morton J. Kern
Spencer B. King III
Neal S. Kleiman
George J. Klein
Robert A. Kloner
Walter J. Koch
Marvin A. Konstam
Raymond T. Kwong
Kathryn G. Lamping
Leslie Leinwand
Bruce B. Lerman
E. Douglas Lewandowski
Martin M. LeWinter
James K. Liao
Peter Libby
Stephen B. Liggett
A. Michael Lincoff
William C. Little
James E. Lock
Douglas W. Losordo
Benedict R. Lucchesi
Lynn Mahony
Alberto Malliani
Donna M. Mancini
Teri Manolio
Eduardo Marbán
Andrew R. Marks
Barry J. Maron
John F. Martin
Attilio Maseri
Jay W. Mason
John E. Mayer, Jr.
Hugh A. McAllister, Jr.
Jeanie B. McMillin
Elizabeth M. McNally
Jawahar L. Mehta
D. Douglas Miller
Jeffrey D. Molkentin
Fred Morady
Ryuichi Morishita
David A. Morrow
Elizabeth Murphy
Charles E. Murry
Anthony J. Muslin
Elizabeth G. Nabel
Ryozo Nagai
Claudio Napoli
Toshio Ogihara

Ira Ockene
Eric N. Olson
William W. O'Neill
Suzanne Oparil
Catherine M. Otto
Milton Packer
Igor F. Palacios
Julio C. Palmaz
Julio A. Panza
Carlo Patrono
Cam Patterson
Dudley J. Pennell
Carl J. Pepine
Joseph K. Perloff
Mark A. Pfeffer
Mariann R. Piano
Michael H. Picard
Peipei Ping
Bertram Pitt
Gerald M. Pohost
Silvia G. Priori
Eric N. Prystowsky
Karin Przyklenk
Reed Pyeritz
Marlene Rabinovitch
Daniel J. Rader
Shahbudin H. Rahimtoola
Nathaniel Reichel
Paul M. Ridker
Jeffrey Robbins
Robert C. Robbins
Robert Roberts
William C. Roberts
Rose Marie Robertson
Michael R. Rosen
Jean-Lucien Rouleau
Marshall S. Runge
Frank M. Sacks
Jeffrey E. Saffitz
David J. Sahn
Andrew I. Schafer
Hartzell V. Schaff
Jutta Schaper
Wolfgang Schaper
Melvin Scheinman
Heinrich R. Schelbert
Ann Marie Schmidt
Arnold Schwartz
Ketty Schwartz
Peter J. Schwartz
Robert J. Schwartz

Robert S. Schwartz
Stephen M. Schwartz
Christine Seidman
Jonathan Seidman
Prediman K. Shah
Maarten L. Simoons
Daniel I. Simon
Paul C. Simpson
Burton E. Sobel
Michael J. Sole
Virend K. Somers
Sidney C. Smith, Jr.
Francis G. Spinale
David H. Spodick
Lynne Warner Stevenson
A. Jamil Tajik
Akira Takeshita
Anne L. Taylor
Pierre Theroux
James D. Thomas
Gianni Tognoni
Gordon F. Tomaselli
Eric J. Topol
Lilliam Valdes-Cruz
Frans J.J. Van de Werf
Dorothy E. Vatner
Stephen F. Vatner
Douglas E. Vaughan
Renu Virmani
Robert A. Vogel
Lars Wallentin
Carole A. Warnes
Hugh Watkins
Karl T. Weber
Keith Webster
William S. Weintraub
James N. Weiss
Stephen Westaby
Josiah N. Wilcox
David O. Williams
Andrew L. Wit
Joseph L. Witztum
Magdi Yacoub
Edward T.H. Yeh
Paul G. Yock
Salim Yusuf
Barry L. Zaret
Andreas M. Zeiher
Michael R. Zile
Douglas P. Zipes
Jay L. Zweier

Special Section Editors

Book Reviews

Thomas J. Ryan

Basic Science for Clinicians

John F. Keaney, Jr.

Clinician Update and Patient Page

Elliott M. Antman

Contemporary Reviews in Cardiovascular Medicine

Ravin Davidoff and Michael A. Fifer

Controversies in Cardiovascular Medicine

Mark E. Josephson

Correspondence

Joseph A. Vita

Images in Cardiovascular Medicine

Warren J. Manning

New Drugs and Technologies

Dan M. Roden and Paul S. Teirstein

Scientific Publishing Committee

Ivor Benjamin, *Chair*Robert Shirrell, *Vice Chair*

Andrew B. Buroker

William Bryson Campbell

N.A. Mark Estes III

Janet H. Fisher

Jerome Kassirer

Rita Redberg

Jeffrey Robbins

Christine E. Seidman

Diane Scott-Lichter

Linda S. Williams

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Editorial Correspondence (Additional information available on the Internet at <http://www.circulationaha.org/misc/about.shtml>)

EDITORIAL CORRESPONDENCE should be sent to Joseph Loscalzo, MD, PhD, Editor, *Circulation*, 560 Harrison Ave, Suite 502, Boston, MA 02118. Phone 617-414-8780. Fax 617-414-8781. E-mail circ@bu.edu

INSTRUCTIONS TO AUTHORS appear in the first issue of each month. Authors should consult these instructions before submitting manuscripts to *Circulation*.

AUTHOR COSTS include page charges, cost of color figures, and cost of reprints, if ordered.

Statements, opinions, and results of studies published in *Circulation* are those of the authors and do not reflect the policy or position of the American Heart Association, and the American Heart Association provides no warranty as to their accuracy or reliability.

Business Correspondence (Additional information available on the Internet at <http://www.circulationaha.org/misc/about.shtml>)

BUSINESS CORRESPONDENCE should be sent to American Heart Association, Lippincott Williams & Wilkins Subscription Fulfillment Dept, 351 West Camden Street, Baltimore, MD 21201-2436. Telephone 800-787-8984. Fax 800-787-8985. E-mail: custserv@lww.com; outside the U.S.: Telephone 410-361-8080; Fax 410-361-8048.

CHANGE OF ADDRESS: Please supply old and new addresses. Allow 4 weeks for changes.

ANNUAL SUBSCRIPTION RATES: U.S.: *Personal* \$303.00; *Institutional* \$576.00; *Single copy* \$17.00. **Outside the U.S.:** *Personal* \$519.00; *Institutional* \$781.00; *Single copy* \$17.00.

Medical professionals and scientists in training may subscribe for \$162 in the United States and \$271 outside the United States if payment is accompanied by a letter from the department chair verifying post held and completion date.

Prepayment is required. Make check, draft, or money order payable to the American Heart Association in US dollars drawn on a US bank, with *Circulation* on the face of the check. To charge with a credit card, include account number, expiration date, and name as it appears on card.

REPRINTS: Authors may purchase reprints of their article by dialing Kathryn Welch, Author Reprint Department, Lippincott Williams & Wilkins at 1-800-341-2258; or, via E-mail at ReprintsGroup@lww.com; an Author Reprint Order Form may be accessed through the Internet at <http://www.services.lww.com/periodicals/author-reprints>. Single copies of reprints are available from the corresponding authors. Reprints in large quantities, for commercial or academic use, may be purchased from the publisher. For information and prices: telephone 410-528-4121, E-mail kgray@lww.com

Advertising Correspondence (Additional information available on the Internet at <http://www.circulationaha.org/misc/about.shtml>)

US ADVERTISING SALES: The Jackson-Gaeta Group, Inc., 33 Smull Avenue, Caldwell, NJ 07006. Telephone 973-403-7677, Fax 973-403-7795. Contact Joe Jackson, Paul Nalbandian, or Charles Novak. For media kits, contact Tina Auletta.

JAPAN ADVERTISING SALES: Biomedis International LTD, ASK Ginza Bldg, 10-6, 7-Chome Ginza, Chuo-ku, Tokyo 104-0061, Japan. Telephone (03) 3575-1611. Fax (03) 3569-0155. Contact Hiromu Furukawa. E-mail hiromu-f@biomedis.co.jp

REST OF WORLD SALES: Fran Grega, 3205 Douglas Point Court, Riva, MD 21140. Telephone 410-956-9861. Fax 410-956-9862. E-mail fgrega@comcast.net

ADVERTISING PRODUCTION: Contact Randy Ezell, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436, telephone 410-528-8533, E-mail rezell@lww.com

SPONSORED GIFT SUBSCRIPTIONS: Contact Carol Bak, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436, telephone 410-528-4163, fax 410-528-4305, E-mail cbak@lww.com

CLASSIFIED ADVERTISING: Contact Jennifer Williams, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436, telephone 1-800-528-1843, E-mail jwilliam@lww.com

Advertisements in this issue have been reviewed to comply with the principles governing advertising in American Heart Association publications. A copy of these principles is available on request. ***The appearance of an advertisement in an AHA publication is neither an AHA guarantee nor endorsement of the product or service or the claims for the product or service made by the advertiser.***

Secondary Services

INDEXED OR ABSTRACTED in *Biological Abstracts*, *CABS*, *CINAHL*, *Chemical Abstracts*, *Current Contents*, *EMBASE/Excerpta Medica*, and *Index Medicus*.

AVAILABLE ONLINE from Ovid Online, 333 Seventh Avenue, 4th Floor, New York, NY 10001. Telephone 800-950-2035.

MICROFORM EDITION available from University Microfilms International, 300 North Zeeb Road, Ann Arbor, MI 48106-1346. Telephone 313-761-4700. Also available from Princeton Microfilm Corporation, Alexander Road, Box 2073, Princeton, NJ 08540. Telephone 609-452-2066.

AUTHORIZATION TO PHOTOCOPY items from this publication for personal and internal use, the personal or internal use of specific clients, or for educational use, is granted by the American Heart Association on the condition that the copier pay the appropriate fee to the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923. Telephone 978-750-8400. Fax 978-750-4744. This consent does not extend to copying for advertising or promotional purposes, for creating new collective works, or for resale. Individuals may make single photocopies for personal, noncommercial use without obtaining permission. For all other use, permission should be sought directly from the Rights & Permissions Desk, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436; telephone 410-528-4016; fax 410-528-8550; E-mail journalpermissions@lww.com

Circulation (ISSN 0009-7322) is published weekly by Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436.

GST Registration Number 89552 4239 RT.

Printed in the USA. © 2004 American Heart Association, Inc.


of membranous RhoA and phosphorylated ERM in brainstem were greater both in angiotensin II-treated rats and SHR than in WKY. Valsartan reduced the expression levels of membranous RhoA in angiotensin II-treated rats and SHR. In addition, Y-27632 or valsartan reduced the expression levels of phosphorylated ERM in both groups. Subcutaneous infusion of phenylephrine increased SBP to the same level of angiotensin II infusion in WKY. However, it did not alter the expression levels of membranous RhoA and phosphorylated ERM. Conclusions: These results suggest that 1) the pressor response induced by central infusion of angiotensin II is substantially mediated by activation of Rho/Rho-kinase pathway in brainstem via AT1 receptors, 2) this pathway may also be involved in hypertensive mechanism in SHR.

1412

Endothelial Nitric Oxide and Hypertension in Autonomic Failure

Alfredo Gamboa, Cyndia Shibao, Andre Diedrich, Bonnie K Black, Ginnie Farley, Satish R Raj, David Robertson, Italo Biaggioni; Vanderbilt Univ, Nashville, TN

More than half of patients with autonomic failure (AF) have severe supine hypertension despite low or unresponsive norepinephrine levels and often undetectable plasma renin activity. Supine hypertension is related to increased vascular resistance but the mechanism is not known. To test the hypothesis that nitric oxide deficiency contributes to supine hypertension we blocked endogenous nitric oxide synthase with L-NMMA in 5 AF patients and 7 normal controls (supine SBP 173 ± 6 and 107 ± 5 mmHg, respectively). Systolic blood pressure (SBP) was normalized to 110 mmHg in AF with graded head-up tilt, and baroreflexes were eliminated with trimethaphan in normal controls to mimic autonomic failure. The pressor response to graded doses of L-NMMA was shifted to the left in AF (Figure). The dose necessary to increase SBP by 30 mmHg was 3.4-fold lower in AF compared to controls (136 ± 24 and 465 ± 103 $\mu\text{g/kg/min}$ respectively, $p < 0.02$). In conclusion, contrary to our original hypothesis, our results suggest an increased tonic release of nitric oxide in AF. Thus, NO deficiency does not contribute to supine hypertension in autonomic failure. On the contrary, this enhanced tonic NO may contribute to orthostatic hypotension in these patients.



1413

Oral Administration of a Mineralocorticoid Receptor Antagonist Reduces Brain, Heart, and Blood-borne Proinflammatory Cytokines in Heart Failure

Yu-Ming Kang, Carver College of Med, Univ of Iowa, Iowa City, IA; Ralph F Johnson, Univ of Iowa, Iowa City, IA; Zhi-Hua Zhang, Carver College of Med, Univ of Iowa, Iowa City, IA; Robert M Weiss, Carver College of Med, Univ of Iowa and VA Med Ctr, Iowa City, IA; Alan K Johnson, Univ of Iowa, Iowa City, IA; Robert B Felder, Carver College of Med, Univ of Iowa and VA Med Ctr, Iowa City, IA

Introduction: Brain and blood-borne cytokines may contribute to neurohumoral excitation in heart failure (HF). We previously reported that blockade of mineralocorticoid receptors (MR) in the central nervous system with spironolactone (SL) reduces circulating tumor necrosis factor (TNF)- α in HF rats. The effect of SL on proinflammatory cytokines (PIC) in the brain and on other important circulating PIC - interleukin (IL)-1 β and IL-6 - was not determined. **Hypothesis:** Chronic treatment with oral SL will reduce brain and blood-borne PIC in rats with HF following MI. **Methods and Results:** Rats underwent coronary artery ligation to induce MI ($48.2 \pm 2.0\%$ of left ventricle, with ejection fraction of $35.5 \pm 4.1\%$ by echocardiography), or sham surgery (SHAM). Six weeks later, immunohistochemistry of the paraventricular nucleus (PVN) of hypothalamus, a region critical to cardiovascular regulation, revealed more PVN neurons (MI vs SHAM, $^{**}P < 0.01$) positive for TNF- α ($59.5 \pm 3.3\%$ vs $10.8 \pm 0.9\%$) and IL-1 β ($70.7 \pm 3.9\%$ vs $13.8 \pm 1.2\%$) in MI ($n=6$) than in SHAM ($n=6$) rats. Double staining demonstrated that these neurons were distributed among PVN neurons expressing Fra-like immunoreactivity, indicating chronic neuronal activation. MI rats ($n=6$) treated with SL (1 mg/kg/day orally for 6 weeks) had fewer (MI+SL vs MI, $^{*}P < 0.01$) Fra-like positive PVN neurons ($85.5 \pm 5.4\%$ vs $183.8 \pm 5.0\%$), and fewer PVN neurons positive for TNF- α ($22.4 \pm 1.8\%$ vs $32.4 \pm 1.7\%$) and IL-1 β ($19.1 \pm 1.3\%$ vs $38.4 \pm 2.1\%$). Levels of TNF- α , IL-1 β and IL-6 in brain and heart tissues and in plasma were also lower in MI rats treated with SL (see table). **Conclusion:** In rats with ischemia-induced heart failure, orally administered SL has a global inhibitory influence on the appearance of proinflammatory cytokines in brain, heart and plasma. The beneficial influence of MR antagonism in patients with HF may result at least in part from blocking aldosterone-induced cytokine synthesis. (Table: $^{*}P < 0.05$ MI+SL vs MI+VEH)

Group	plasma IL-1 β (pg/ml)	plasma IL-6 (pg/ml)	heart IL-1 β (pg/mg protein)	hypothalamus IL-1 β (pg/mg protein)	hypothalamus TNF- α (pg/mg protein)	brainstem TNF- α (pg/mg protein)	brainstem IL-6 (pg/mg protein)	cortex IL-1 β (pg/mg protein)	heart BW Ratio	lung BW Ratio
MI+VEH (n=7)	131.1 \pm 10.9	119.5 \pm 9.7	53.4 \pm 6.5	47.1 \pm 7.9	6.8 \pm 0.7	6.1 \pm 0.9	67.1 \pm 10.1	26.4 \pm 4.1	7.2 \pm 0.2	13.5 \pm 0.6
MI+SL (n=7)	57.5 \pm 3.1 *	53.3 \pm 6.6 *	32.8 \pm 5.9 *	29.4 \pm 5.1 *	3.6 \pm 0.6 *	2.8 \pm 0.5 *	38.4 \pm 5.5 *	25.8 \pm 5.2	6.4 \pm 0.3 *	12.1 \pm 0.6 *
SHAM+SL (n=8)	48.2 \pm 3.6	33.7 \pm 2.8	23.7 \pm 6.5	17.4 \pm 4.8	2.8 \pm 0.7	2.1 \pm 0.6	25.3 \pm 4.8	24.3 \pm 4.9	3.3 \pm 0.1	5.2 \pm 0.3
SHAM+VEH (n=8)	53.9 \pm 2.4	36.1 \pm 2.8	27.8 \pm 5.4	18.8 \pm 4.0	3.2 \pm 0.8	2.4 \pm 0.8	26.0 \pm 6.7	23.6 \pm 6.5	3.4 \pm 0.1	5.1 \pm 0.3

Pulmonary Arterial Hypertension: New Therapies

Subspecialty: Integrative Biology

Wednesday

Ernest N Morial Convention Center, Hall 12

Abstracts 1414-1418

1414

Inhaled Treprostinil Sodium (TRE) For the Treatment of Pulmonary Hypertension

Robert Voswinckel, Beate Enke, Andre Kreckel, Frank Reichenberger, Stefanie Krick, Henning Gall, Tobias Gessler, Thomas Schmehl, Markus G Kohstall, Friedrich Grimminger, Hossein A Ghofrani, Werner Seeger, Horst Olschewski; Univ Hosp Giessen, Giessen, Germany

Objective: To evaluate the effects of inhaled TRE on pulmonary hemodynamics and gas exchange in severe pulmonary hypertension (PH) and to assess safety, tolerability and clinical efficacy in patients with severe PH. **Background:** TRE is a stable prostacyclin analogue that has been approved for treatment of pulmonary arterial hypertension as a continuous subcutaneous infusion. Iloprost, another prostacyclin analogue, has been shown to be efficacious in a randomised controlled study as repetitive inhalation. **Methods:** In an open-label study a preservative free solution of inhaled TRE was applied to 17 patients with severe pulmonary hypertension during Swan-Ganz catheter investigation. Patients received a TRE inhalation by use of the pulsed OptiNeb $^{\text{®}}$ ultrasound nebulizer (3 single breaths, TRE solution 600 $\mu\text{g/ml}$). Hemodynamics were observed for 2 hours. Two patients with idiopathic PAH received compassionate treatment with 4 inhalations of TRE per day after the acute test. **Results:** Patients (male/female = 4/13) suffered from iPAH ($n=5$), PAH other ($n=8$) and CTEPH ($n=4$). PVR 948 ± 112 $\text{dyn}\cdot\text{s}\cdot\text{cm}^{-5}$, PAP 48.3 ± 2.7 mmHg, PAWP 8.9 ± 0.5 mmHg, CVP 10.8 ± 1.6 mmHg, CO 3.8 ± 0.3 l/min, SvO $_2$ $61.8 \pm 1.8\%$. TRE inhalation resulted in a sustained, highly pulmonary selective vasodilatation over 120 minutes. Maximum PVR decrease was $-31.2 \pm 4.5\%$ after 30 min. PVR and SVR at 120 minutes after inhalation were $89.2 \pm 4.2\%$ and $101.0 \pm 4.0\%$ of the baseline values, respectively. The AUC for the observation period (120min) was $-22.9 \pm 3.8\%$ for PVR and $-4.9 \pm 3.2\%$ for SVR. The compassionate use patients have been treated for more than 3 months. In both patients NYHA class improved (from IV to III and from III to II), and six minute walk increased (from 0 m (bedridden) to 143 m, and from 310 m to 486 m, respectively). No side effects have been observed by the patients during long-term treatment. **Conclusion:** Inhaled TRE shows strong pulmonary selective vasodilatory efficacy with a long duration of effect following single acute dosing. Tolerability is excellent even at high drug concentrations and short inhalation times (3 breaths). Long-term treatment effects are very promising. The current results warrant controlled studies investigating this approach in a larger series of patients. Supported by Lung RX

1415

Rho-kinase in Pulmonary Hypertension

Ken Ishikura, Norikazu Yamada, Akihiro Tsuji, Satoshi Ota, Mashio Nakamura, Masaaki Ito, Naoki Isaka, Takeshi Nakano; Mie Univ Sch of Med, Tsu, Japan

Objectives: Pulmonary hypertension (PH) is a poor prognostic disease with limited treatment. Rho-kinase is involved in the pathophysiology of several diseases underlying smooth muscle hypercontraction. But the role of it is unknown. The purpose of this preliminary report was to indicate the efficacy of fasudil, a Rho-kinase inhibitor in patients with pulmonary hypertension using interventional hemodynamic assessment. **Methods:** Fasudil was intravenously injected in 10 patients (9 female, mean \pm SD, 46 ± 15 years, NYHA II $n=2$, III $n=7$, IV $n=1$) with primary ($n=5$) and secondary ($n=5$) PH who were not received any vasodilator. Fasudil was administered 30mg with 1mg/min. Hemodynamic data were measured using Swan-Ganz catheter until 60 minutes after starting administration of fasudil. Hemodynamic and arterial blood gas data of baseline and the lowest total pulmonary resistance (TPR) time were compared. **Results:** The lowest TPR time was within 30 to 60 minutes after administration. Administration of fasudil significantly decreased TPR from 13.6 ± 6.8 U to 10.3 ± 4.9 U ($-23.2 \pm 9.2\%$, $p < 0.001$) and mean pulmonary arterial pressure (mPAP) from 43.6 ± 14.5 mmHg to 38.8 ± 13.9 mmHg ($-11.6 \pm 10.4\%$, $p < 0.02$). Cardiac index (CI) was significantly increased from 2.39 ± 0.66 l/min/m 2 to 2.74 ± 0.73 l/min/m 2 ($+16.5 \pm 15.1\%$, $p < 0.01$). Although TPR was equally decreased in both primary and secondary PH, the changes in the parameters that prescribed TPR, namely CI and mPAP, were different between the two groups subjects. Increased CI was a major factor into reducing TPR in primary PH, while reduced mPAP